Effect of menopausal hormone therapy on COVID-19 severe outcomes in women – A population-based study of the US National COVID Cohort Collaborative (N3C) data

Whether menopausal hormone therapy (MHT) lessens the severity of COVID-19 among women is unclear. Leveraging a U.S. national COVID-19 cohort and a cross-sectional analysis, we found MHT use was marginally associated with a lower risk of mortality (odds ratio [OR] 0.73, 95 % CI 0.53–1.01) and signifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoshida, Yilin, Chu, San, Zu, Yuanhao, Fox, Sarah, Mauvais-Jarvis, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier B.V. 2023
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633103/
https://www.ncbi.nlm.nih.gov/pubmed/36773498
http://dx.doi.org/10.1016/j.maturitas.2022.10.005
Descripción
Sumario:Whether menopausal hormone therapy (MHT) lessens the severity of COVID-19 among women is unclear. Leveraging a U.S. national COVID-19 cohort and a cross-sectional analysis, we found MHT use was marginally associated with a lower risk of mortality (odds ratio [OR] 0.73, 95 % CI 0.53–1.01) and significantly associated with a lower risk of prolonged hospital stay (0.7, 0.49–0.99) among inpatient women. When stratifying by MHT type, estrogen-only and estrogen-plus-progestin therapies had a more prominent protective effect than progestin-only therapy, although this difference did not achieve statistical significance. Women with COVID-19 can continue to use MHT. Clinical trials are needed to evaluate MHT's therapeutic effect on COVID-19, especially in terms of severity.

Ejemplares similares